The FDA approved Beovu for the treatment of diabetic macular edema, Novartis announced in a press release.
This new indication follows the previous approval of Beovu (brolucizumab, Novartis) 6 mg for wet age-related macular degeneration in 2019 and was based on 1-year data from the phase 3 KESTREL and KITE clinical trials comparing the efficacy and safety of brolucizumab with aflibercept.
According to Carl D. Regillo, MD, an investigator in both trials, Beovu is a “welcome addition to the current anti-VEGF treatment options in managing DME.”
“Having brolucizumab FDA approved for treating DME is good news for our patients,” he told Healio/OSN. “The phase 3 clinical trials showed better drying of the macula with brolucizumab compared to aflibercept and also the potential for increased durability, both of which may lead to improved visual outcomes for some patients with DME.”…..
Read more: https://www.healio.com/news/ophthalmology/20220601/beovu-receives-fda-approval-for-new-indication-in-diabetic-macular-edema?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=214789326967